Silviu Itescu, Mesoblast CEO
Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
About two and a half months after the FDA turned away their lead program, Mesoblast $MESO reported a Phase III miss Monday afternoon for their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
